Sponsors considering the FSP model often focus on what they gain, but the more useful starting question is what they can afford to manage. The global FSP market was valued at $15.43 billion in 2024 and is on a path to $38.56 billion by 2035, a trajectory that reflects how many development organizations have concluded that outsourcing an entire study costs more control than they want to give up. The appeal is real: FSP arrangements have been shown to reduce study costs by 15% to 30% compared to full-service outsourcing, largely because sponsors pay for specific functions rather than absorbing a CRO’s full operational overhead.
The practical difference between FSP and full-service outsourcing comes down to accountability architecture. Under FSP, the sponsor retains strategic ownership and oversight of an outsourced function, say biostatistics or data management, while the partner supplies specialist staff, defined processes, and delivery frameworks. The FSP team often works within sponsor systems and SOPs, which helps keep institutional knowledge in-house. Under full-service outsourcing, the CRO brings its own systems and absorbs day-to-day operational responsibility across multiple functions, which reduces management burden but also reduces visibility. The choice is not about which model is better in the abstract; it is about where the sponsor’s internal governance is strong enough to hold oversight without becoming a bottleneck.
That oversight requirement is not optional. ICH E6(R2) places explicit quality and oversight obligations on sponsors regardless of how much they outsource, which means an FSP arrangement that lacks defined governance structures, service level agreements, and performance metrics falls short of what leading providers and sponsors expect from a well-structured partnership. The model delivers its value in ongoing programs with consistent functional demand. For isolated, single-study work, the coordination overhead of managing an FSP partner can erode the cost and flexibility benefits before the program is far enough along to realize them.
Many organizations ultimately run both models in parallel across their portfolio, selecting FSP where they have internal infrastructure to oversee it and full-service CRO engagement where they do not. The governance capacity question comes first; the outsourcing model follows from the answer.
Source link: https://phastar.com/knowledge-centre/blogs/is-the-fsp-model-right-for-your-clinical-program/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
